Loading
A phase 2 trial of Pixantrone, Ifosfamide, Etoposide and Rituximab in Non-Hodgkin lymphoma, run by The Lymphoma Academic Research Organisation, completed.
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma is a phase 2 interventional study registered as NCT03458260 by The Lymphoma Academic Research Organisation, with 74 participants recorded, started 2018-12-26 and reaching its primary completion in 2024-12-24. Interventions recorded: Pixantrone, Ifosfamide, Etoposide, Rituximab, Transplant. Conditions recorded: Aggressive Non-Hodgkin Lymphoma.
Linked to the drug Pixantrone because the registry names it among its interventions and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pixantrone and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Ifosfamide, Etoposide, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Ifosfamide and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Etoposide and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/